

US009511074B2

(12) United States Patent

Perlmutter et al.

(10) Patent No.: US 9,511,074 B2

(45) **Date of Patent: Dec. 6, 2016**

(54) METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN POLYMERIZATION

(71) Applicant: UNIVERSITY OF

PITTSBURGH—OF THE

COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh,

PA (US)

(72) Inventors: David Hirsch Perlmutter, Pittsburgh,

PA (US); George Konstantine Michalopoulos, Pittsburgh, PA (US); Tunde Hidvegi, Gibsonia, PA (US)

(73) Assignee: UNIVERSITY OF

PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh,

PA (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

(21) Appl. No.: 14/535,210

(22) Filed: Nov. 6, 2014

(65) Prior Publication Data

US 2015/0065488 A1 Mar. 5, 2015

Related U.S. Application Data

- (63) Continuation of application No. 13/362,606, filed on Jan. 31, 2012, now Pat. No. 8,906,905, which is a continuation-in-part of application No. PCT/US2010/044243, filed on Aug. 3, 2010.
- (60) Provisional application No. 61/230,921, filed on Aug. 3, 2009.
- (51) Int. Cl. A61K 31/55 (2006.01) A61K 31/155 (2006.01)
- (52) U.S. Cl. CPC A61K 31/55 (2013.01); A61K 31/155 (2013.01)

(56) References Cited

U.S. PATENT DOCUMENTS

5,658,900	A	8/1997	Boireau et al.
5,780,483	A	7/1998	Widdowson et al.
8,809,617	B2	8/2014	Pak et al.
2003/0023997	A1	1/2003	Peraus et al.
2003/0224508	A1	12/2003	Ill et al.
2004/0213771	A1	10/2004	Sluder et al.
2006/0079556	A1	4/2006	Sher et al.
2006/0141625	A1	6/2006	Sisk et al.
2007/0275957	$\mathbf{A}1$	11/2007	Weiner et al.
2009/0087916	A1	4/2009	Sato et al.
2010/0076018	$\mathbf{A}1$	3/2010	Liu et al.

2010/0263062 A1	10/2010	Dillin et al.
2011/0154510 A1	6/2011	Pak et al.
2012/0129839 A1	5/2012	Perlmutter et al.
2014/0047569 A9	2/2014	Pak et al.
2014/0331341 A1	11/2014	Pak et al.

FOREIGN PATENT DOCUMENTS

CN	101023944			8/2007	
WO	WO 94/18972			9/1994	
WO	WO 96/30766			10/1996	
WO	WO 98/28971			7/1998	
WO	WO 98/48784			11/1998	
WO	WO 00/63427	A2		10/2000	
WO	WO 00/73510	A1		12/2000	
WO	WO 01/60840	A3		8/2001	
WO	WO 02/096431			12/2002	
WO	WO 2005/011610			2/2005	
WO	WO 2008/030617	A2		3/2008	
WO	WO 2008/092898	A1		8/2008	
WO	WO 2008097924	A2	*	8/2008	A61K 31/473
WO	WO 2009/036275			3/2009	
WO	WO 2009/039284	A1		3/2009	
WO	WO 2009/049242			4/2009	
WO	WO 2010085452	A1	*	7/2010	A61K 31/11

OTHER PUBLICATIONS

U.S. Appl. No. 12/881,976, Jul. 7, 2014 Issue Fee payment.

U.S. Appl. No. 12/881,976, Apr. 11, 2014 Notice of Allowance.

U.S. Appl. No. 12/881,976, Nov. 25, 2013 Amendment and Request for Continued.

U.S. Appl. No. 12/881,976, Nov. 7, 2013 Advisory Action.

U.S. Appl. No. 12/881,976, Oct. 21, 2013 Response to Final Office Action.

U.S. Appl. No. 12/881,976, Jul. 19, 2013 Final Office Action.

U.S. Appl. No. 12/881,976, May 13, 2013 Response to Non-Final Office Action.

U.S. Appl. No. 12/881,976, Dec. 11, 2012 Non-Final Office Action. U.S. Appl. No. 12/881,976, Aug. 13, 2012 Response to Restriction Requirement.

U.S. Appl. No. 12/881,976, Jul. 13, 2012 Restriction Requirement. U.S. Appl. No. 13/362,606, Nov. 6, 2014 Issue Fee payment.

(Continued)

Primary Examiner — Samira Jean-Louis (74) Attorney, Agent, or Firm — Baker Botts L.L.P.

(57) ABSTRACT

The present invention relates to methods of treatment of clinical disorders associated with protein polymerization comprising administering, to a subject, an effective amount of carbamazepine, oxcarbazepine or another carbamazepine-like compound. It is based, at least in part, on the discovery that, in cells having a genetic defect in $\alpha 1$ -antitrypsin, carbamazepine was able to decrease levels of the mutant protein. Furthermore, carbamazepine reduced the hepatic load of mutant $\alpha 1$ -antitrypsin and the toxic effect of that mutant protein accumulation, hepatic fibrosis, in vivo using a mouse model of the disease. As patients having this defect in $\alpha 1$ -antitrypsin exhibit toxic accumulations of the protein, treatment according to the invention may be used to ameliorate symptoms and signs of disease.